To honor Bladder Cancer Awareness Month this May, CURE® is taking a look at some of the most recent updates in the disease space.
- In a recent episode of the “CURE® Talks Cancer” podcast, we spoke with a cancer research writer, Henry Scowcroft, about his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.
- In April, the Food and Drug Administration (FDA) granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for patients with locally advanced or metastatic urothelial cancer, who have previously received platinum chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
- Overall survival and progression-free survival did not significantly differ when adjusting the dose of cisplatin in combination with Abraxane (paclitaxel protein-bound) and gemcitabine in patients with advanced/metastatic urothelial carcinoma, according to a study published in Urologic Oncology.
- In early March, Tecentriq’s (atezolizumab) indication for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy was pulled by the FDA and the drug’s manufacturer, Roche.
- While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale, co-founder of the Bladder Cancer Advocacy Network (BCAN).
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.